Furthermore, there are clinical trials in phase 2 or 3 using anti-CCN2 therapies in Duchenne muscular dystrophy (NCT02606136), pancreatic adenocarcinoma (NCT04229004) and idiopathic pulmonary fibrosis (NCT03955146). Here, CCN2 is linked to Duchenne muscular dystrophy.